LIB Therapeutics
As of the edition of 20 October 2026, LIB Therapeutics runs 1 drug, 1 of them marketed; it is on route A at 0 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Total | 1 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Lerodalcibep | Ends 2037 (computed from the first US licence) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 1 target.
| Target | Route |
|---|---|
| PCSK9 Proprotein convertase subtilisin/kexin type 9 | Route B |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where LIB Therapeutics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nutrition and metabolism: 7 trials led
- Heart and blood vessels: 3 trials led
- Inherited and neonatal: 2 trials led